Jaiswal continues: “We met with investors in Kuala Lumpur to discuss the Asean healthcare outlook. Investors were more keen on Thailand and Indonesia healthcare stocks, and still had concerns on Singapore’s private healthcare sector and Raffles Medical.”
RHB Bank Singapore analyst Shekhar Jaiswal is keeping his “neutral” call on Raffles Medical Group (SGX:BSL
) with an unchanged target price of $1.06.
He writes in his July 1 report: “While Raffles Medical’s valuation looks compelling relative to regional healthcare stocks, we do not see any near-term re-rating catalysts.”
